Brazil Cancer Pain Management Market Report 2022 to 2030

Brazil Cancer Pain Management Market Analysis

$ 3999

The Brazil Cancer Pain Management market is projected to grow from $163 Mn in 2022 to $265.74 Mn by 2030, registering a CAGR of 6.3% during the forecast period of 2022 - 2030. The main factors driving the growth would be increased incidences of cancer, an ageing population, the growing pharmaceutical industry and supportive government policies. The market is segmented by drug type and by disease. Some of the major players include Grunenthal Pharma, Hisamitsu Pharmaceutical, Mundipharma, Pfizer, Teva Pharmaceuticals and Abbott.

ID: IN10BRHS002 CATEGORY: Healthcare Services GEOGRAPHY: Brazil AUTHOR: Neha Davda

Buy Now

Brazil Cancer Pain Management Market Executive Summary

The Brazil Cancer Pain Management market is projected to grow from $163 Mn in 2022 to $265.74 Mn by 2030, registering a CAGR of 6.3% during the forecast period of 2022 - 2030. In 2019, Brazil's healthcare spending as a percentage of GDP was 9.59% or $853 per person. Although there has been a lot of recent volatility, Brazil's health spending as a proportion of GDP tended to rise between 2000 and 2019.

Brazil has a high prevalence of cancer and a huge population that need pain management services, hence the market for cancer pain treatment there is expanding. The market offers a variety of goods and services, such as painkillers, palliative care, and non-pharmacological pain relief methods. Notwithstanding the difficulties the healthcare system faces, improvements in cancer pain management have been made in Brazil recently. A national pain management strategy was introduced by the Brazilian Ministry of Health in 2019, with the goals of expanding access to cancer pain management drugs and encouraging the use of non-pharmacological pain reduction methods.

Brazil Cancer Pain Management Market

Market Dynamics

Market Growth Drivers

The Brazil cancer pain management market is expected to be driven by factors such as increasing incidences of cancer, an ageing population, a growing pharmaceutical industry and supportive government policies. The Brazilian government has put laws into place to increase access to medications, like lowering import duties on opioid pharmaceuticals. As a result, the market is anticipated to grow and the demand for these medications would rise.

Market Restraints

Opioids and other medications are difficult to obtain in Brazil because of legal restrictions and concerns about abuse and addiction. For cancer patients, this makes it challenging to have access to efficient pain management and restricts the market growth

Competitive Landscape

Key Players

Grunenthal Pharma
Hisamitsu Pharmaceutical Co
Mundipharma
Pfizer
Teva Pharmaceuticals
Abbott

Notable Recent Deals

December 2021: Hisamitsu Pharmaceutical and RaQyalia Pharma have decided to sign a licence agreement for a brand-new sodium channel blocker. Prior to going to the clinical stage, Hisamitsu Pharmaceutical will perform preclinical research on new pain treatment drug(s) containing the molecule using its expertise in manufacturing transdermal pharmaceuticals. The development, manufacture, and marketing of the substance will be provided to Hisamitsu Pharmaceutical as the only worldwide rights under the licencing agreement.

Healthcare Policies and Regulatory Landscape

Numerous laws and regulations govern the regulatory environment in Brazil for the treatment of cancer pain. The National Health Surveillance Agency (ANVISA) is the principal regulatory organisation in charge of monitoring the clearance of drugs and related laws. ANVISA is in charge of assessing the efficacy and safety of medications and medical equipment, particularly those employed in the treatment of pain.

In terms of healthcare laws, Brazil's Unified Health System (SUS), a public healthcare system, offers free medical care to all people. A palliative care programme is part of the SUS, and it works to enhance the quality of life for those with cancer and other chronic illnesses. The program's core element of care also involves pain management.

Reimbursement Scenario

The Unified Health System (SUS), Brazil's public healthcare system, mostly determines reimbursement standards for cancer pain management. All people are entitled to free healthcare from the SUS, which also pays for the cost of drugs and therapies for pain control in cancer patients. The SUS's coverage does have some restrictions, though. For instance, there can be limitations on the kinds and amounts of painkillers that can be prescribed, and patients might need to fulfil specific requirements to be eligible for coverage.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

The Brazil Cancer Pain Management market is projected to grow from $163 Mn in 2022 to $265.74 Mn by 2030, registering a CAGR of 6.3% during the forecast period of 2022 - 2030.

The Brazil cancer pain management market is segmented by drug type (opioids, morphine, non-opioids, acetaminophen, non-steroidal anti-inflammatory drugs and nerve blockers) and by disease indication (lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer and others).

Some of the major players in Brazil's cancer pain management market are Grunenthal Pharma, Hisamitsu Pharmaceutical, Mundipharma, Pfizer, Teva Pharmaceuticals and Abbott.